CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes by Buckingham, Bruce et al.
CGM-measured glucose values have a strong correlation with C-
peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide 
levels in the two years following onset of diabetes
Bruce Buckingham1, Peiyao Cheng2, Roy W. Beck2, Craig Kollman2, Katrina J. Ruedy2, 
Stuart A. Weinzimer3, Robert Slover4, Andrew A. Bremer5, John Fuqua6, and William 
Tamborlane3 for the Diabetes Research in Children Network (DirecNet) and Type 1 
Diabetes TrialNet Study Groups
1Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA
2Jaeb Center for Health Research, 15310 Amberly Drive Suite 350, Tampa, FL 33647, USA
3Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA
4Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, 
Aurora, CO, USA
5Division of Pediatric Endocrinology, Vanderbilt University School of Medicine, Nashville, TN, 
USA
6Department of Pediatric Endocrinology, Indiana University School of Medicine, Indianapolis, IN, 
USA
Abstract
Aims/hypothesis—The aim of this work was to assess the association between continuous 
glucose monitoring (CGM) data, HbA1c, insulin-dose-adjusted HbA1c (IDAA1c) and C-peptide 
responses during the first 2 years following diagnosis of type 1 diabetes.
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Methods—A secondary analysis was conducted of data collected from a randomised trial 
assessing the effect of intensive management initiated within 1 week of diagnosis of type 1 
diabetes, in which mixed-meal tolerance tests were performed at baseline and at eight additional 
time points through 24 months. CGM data were collected at each visit.
Results—Among 67 study participants (mean age [± SD] 13.3 ± 5.7 years), HbA1c was inversely 
correlated with C-peptide at each time point (p < 0.001), as were changes in each measure 
between time points (p < 0.001). However, C-peptide at one visit did not predict the change in 
HbA1c at the next visit and vice versa. Higher C-peptide levels correlated with increased 
proportion of CGM glucose values between 3.9 and 7.8 mmol/l and lower CV (p = 0.001 and 
p=0.02, respectively) but not with CGM glucose levels < 3.9 mmol/l. Virtually all participants 
with IDAA1c < 9 retained substantial insulin secretion but when evaluated together with CGM, 
time in the range of 3.9–7.8 mmol/l and CV did not provide additional value in predicting C-
peptide levels.
Conclusions/interpretation—In the first 2 years after diagnosis of type 1 diabetes, higher C-
peptide levels are associated with increased sensor glucose levels in the target range and with 
lower glucose variability but not hypoglycaemia. CGM metrics do not provide added value over 
the IDAA1c in predicting C-peptide levels.
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Introduction
Partial recovery of endogenous insulin production (measured by C-peptide secretion) in the 
first few months after the onset of type 1 diabetes results in a significant restoration of 
glycaemic control with lower doses of exogenous insulin, commonly referred to as the 
remission or ‘honeymoon’ phase of type 1 diabetes [1, 2]. The Diabetes Control and 
Complications Trial (DCCT) [3] demonstrated that even beyond the first year of insulin 
treatment, maintenance of measurable C-peptide secretion was associated with significantly 
lower HbA1c levels, reduced insulin dose requirements and a reduced risk of hypoglycaemia 
when compared with patients without residual beta cell function. The DCCT also showed 
that better metabolic control of diabetes though intensive insulin therapy could slow the rate 
of loss of residual insulin secretion [3]. More recently, Mortensen and colleagues 
demonstrated that an insulin-dose-adjusted HbA1c level (IDAA1c = HbA1c [%] + 4 × total 
daily insulin dose [U/kg body weight]) < 9.0 is a metric that consistently predicts substantial 
residual endogenous insulin secretion in young people with type 1 diabetes [4].
We recently completed a randomised trial that evaluated whether intensive diabetes 
management initiated within the first week of treatment of type 1 diabetes with an initial 
period of inpatient closed-loop insulin delivery followed by outpatient sensor-augmented 
pump (SAP) therapy could lead to greater preservation of beta cell function as compared 
with conventional intensive insulin therapy [5]. In both the intensive group and standard 
(usual care) treatment groups, data on insulin use were collected, HbA1c levels were 
measured and residual C-peptide responses to mixed-meal tolerance tests (MMTTs) were 
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determined during frequent follow-up visits over the first 2 years of treatment. In this study, 
the intensively treated participants were asked to use their SAP continuously using the 
Medtronic MiniMed Sof-Sensor, and the usual-care group wore a blinded Medtronic 
Guardian CGM for 3 days after each visit. Since the patterns of changes in HbA1c levels and 
C-peptide responses did not differ between the two treatment groups, we were able to pool 
the results from both treatment groups to examine the impact of changes in residual insulin 
secretion over time on CGM indices of glycaemic control, as well as on changes in HbA1c 
levels. We also sought to determine whether CGM data could be used, like the IDAA1c, as a 
metric to predict C-peptide levels in patients with type 1 diabetes. CGM is now commonly 
available and, unlike an MMTT, does not require admission to a research unit, or an 
intravenous line with multiple blood draws and C-peptide assays. If use of CGM data could 
serve as a surrogate for determining C-peptide levels by MMTT then there would be 
multiple benefits to the patient (no admission, no time lost from work and no intravenous 
catheter or multiple blood draws) as well as economic advantages (costs of the admission, 
blood processing, C-peptide assays and personnel time). In this study we therefore assessed 
several CGM indices of glycaemic control (per cent in range during the day and overnight 
and glycaemic variability) as surrogate measures of residual C-peptide secretion during the 
early phase of type 1 diabetes treatment.
Methods
The randomised trial in which the data for this secondary analysis was collected was 
conducted at five clinical centres and was approved by each of the local institutional review 
boards. Written informed consent was obtained from adult patients and parents/guardians of 
minor patients, who themselves also provided written assent. The study is listed on 
www.clinicaltrials.gov (registration no. NCT00760526) and the full protocol is available 
online (http://direcnet.jaeb.org/Studies.aspx). The methods for the randomised trial have 
previously been described [5]. In brief, 67 individuals (aged 7–45 years, mean [± SD] 13.3 ± 
5.7 years; all but three were < 18 years old) with positive pancreatic autoantibodies were 
enrolled within 6 days of diagnosis of type 1 diabetes (mean 2.9 ± 1.7 days). Participants 
were randomly assigned to the intensive group or usual-care group in a 2: 1 ratio. The 
intensively treated group received 3 days of hybrid closed-loop control (HCLC) using the 
Medtronic MiniMed ePID system (Medtronic MiniMed, Northridge, CA, USA) [6–8] 
followed by SAP therapy while the usual-care group received standard diabetes 
management. Study visits occurred 2, 6 and 13 weeks after study entry and every 3 months 
thereafter until 2 years. All 67 participants completed the 12 month visit and 65 completed 
the 24 month visit.
Two hour MMTTs were performed to measure residual C-peptide levels using the standard 
TrialNet protocol [9, 10] at study entry, at 2 and 6 weeks, and at 3, 6, 9, 12, 18 and 24 
months. HbA1c was measured at the Northwest Lipid Metabolism and Diabetes Research 
Laboratories using a dedicated TOSOH analyser (Biosciences, South San Francisco, CA, 
USA) and insulin use data were collected to calculate the IDAA1c, as previously described 
[4]. CGM data were collected using the Medtronic MiniMed Sof-Sensor. For the intensive-
treatment group, the CGM was downloaded at each visit. For the usual-care group, a blinded 
Medtronic Guardian CGM was worn for 3 days after each visit. CGM data were available 
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for 267 (82%) of 327 completed visits in the intensively treated group and 98 (77%) of 128 
completed visits in the usual-care group. The median number of hours of CGM data used for 
analysis at each visit was 168 (interquartile range 94–266) h in the intensive group and 70 
(interquartile range 66–72) h in the usual-care group.
Total daily insulin doses were obtained from pump downloads for those using an insulin 
pump. For those using multiple daily injections (MDI), insulin doses were obtained at the 
time of a visit by asking participants and their parents about their usual pre-meal and pre-
snack insulin doses as well as their usual daily basal insulin doses.
The peak MMTT C-peptide level was highly correlated with C-peptide AUC (Spearman r = 
0.95–1.00, electronic supplementary material [ESM] Fig. 1) and was used as a measure of 
residual C-peptide secretion. Since there were no treatment-group differences in peak C-
peptide levels at any time points, as previously reported [5], data from both groups were 
pooled for the analyses. All C-peptide values were transformed into a log scale using the 
formula y = loge (x + 1) due to the non-normal distribution of the data.
Spearman correlation calculations were used to assess the cross-sectional association of 
HbA1c, IDAA1c [4] and CGM indices with C-peptide levels at each visit. Repeated measure 
least square models were used to assess the longitudinal associations, with within-subject 
effect and between-subject effect evaluated separately. The associations between CGM 
glucose indices, IDAA1c and C-peptide levels also were assessed at each visit to determine 
whether CGM measurements had an additional advantage beyond IDAA1c as a predictor of 
C-peptide levels.
Results
There was a gradual decline in C-peptide levels over the 2 years of the study and the 
percentage of participants with a peak C-peptide level > 0.2 pmol/ml decreased from 98% at 
3 months to 59% at 24 months (ESM Fig. 2).
Association of CGM glycaemic indices with C-peptide levels
The proportion of CGM-measured glucose values between 3.9 and 7.8 mmol/l was 
consistently associated with peak C-peptide levels across visits (p = 0.001 for both within-
subject effect and between-subject effect, Table 1). When 60% or more of the sensor values 
were in the range of 3.9–7.8 mmol/l, the peak C-peptide level was always > 0.2 pmol/ml. 
However, for a given percentage of glucose values in this range, there was a broad range of 
peak C-peptide levels (Fig. 1a). When evaluated together with IDAA1c, time, for glucose 
values in the range of 3.9–7.8 mmol/l, did not provide additional value in predicting C-
peptide levels (Table 1). There was a broad range of peak C-peptide levels for a given 
fasting CGM glucose level (readings between 04:00 and 06:00 hours) (Fig. 1b). If at least 
40% of the fasting CGM measurements were within range, then 96% of the time the peak C-
peptide level was > 0.2 pmol/ml. The positive predictive value for a given C-peptide level to 
predict the percentage of glucose values in range or for the percentage of glucose values in 
range to predict a C-peptide level was weak, Table 2.
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With respect to hypoglycaemia, peak C-peptide levels did not predict the percentage of 
glucose readings < 3.9 mmol/l, and individuals with peak C-peptide levels of 0.6–1.4 
pmol/ml could still have frequent hypoglycaemic readings (Fig. 2a). With respect to glucose 
variability, higher peak C-peptide levels were associated with lower glucose variability (p = 
0.02) (Fig. 2b). However, when evaluated together with IDAA1c, glucose variability did not 
provide additional value in predicting C-peptide levels (Table 3).
Association of C-peptide levels and HbA1c
For each individual and for the group as a whole, there was a correlation between peak C-
peptide level and HbA1c level across time points (p < 0.001 and p = 0.01, respectively, for 
within-subject and between-subject effects, ESM Table 1). At all time points where the 
HbA1c level was < 6.0% (42 mmol/mol) the peak C-peptide level was > 0.2 pmol/ml. There 
was, however, a broad range of C-peptide levels for each HbA1c level and a broad range of 
HbA1c levels for each peak C-peptide level (Fig. 3); so, the positive predictive value for a 
given C-peptide level to predict an HbA1c level or for an HbA1c level to predict a C-peptide 
level was weak.
There also was an association between changes in C-peptide levels between time points and 
changes in HbA1c levels between time points (p < 0.001 for both within-subject effect and 
between-subject effect) (ESM Table 2). However, longitudinal data showed that the HbA1c 
level at a particular visit did not predict the change in C-peptide levels at the subsequent 
visit and likewise peak C-peptide levels at a visit did not predict the change in HbA1c levels 
at the next visit (ESM Fig. 3).
Association of C-peptide levels and IDAA1c
IDAA1c levels and C-peptide levels were associated at each visit (p ≤ 0.001) (ESM Table 3) 
as were changes between visits in IDAA1c and C-peptide levels (p = 0.03 to < 0.001) (ESM 
Table 4). In 99% of cases, when IDAA1c was < 9, peak C-peptide levels were > 0.2 pmol/ml 
compared with only 40% when IDAA1c was ≥ 12 (ESM Table 5).
Discussion
This analysis provided a rich dataset for evaluating the associations of C-peptide levels, 
HbA1c and CGM measures of time in range, hypoglycaemia, and glucose variability early in 
the course of type 1 diabetes through both cross-sectional and longitudinal analyses. There 
was a strong correlation at all time points for the percentage of CGM values between 3.9 and 
7.8 mmol/l and peak C-peptide levels > 0.2 pmol/ml (p = 0.001). Although we found strong 
statistical associations between C-peptide levels, CGM measures and IDAA1c levels at each 
time point as well as in changes from one time point to the next, CGM indices were not 
predictive of C-peptide levels after accounting for IDAA1c.
The only other published study using CGM data as a marker of C-peptide secretion involved 
islet transplantation in which CGM data were used as a measure of graft function (C-peptide 
secretion) [11]. In that study, a composite score was used to assess graft survival (the β-
score [12]) and the peak C-peptide level following an MMTT was not specifically measured; 
eight subgroups were used for the β-score, whereas we had a continuous variable (peak C-
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peptide concentration). They found a strong negative association between the β-score 
(higher score equals more graft function) and the mean CGM blood glucose level (r = 
−0.65), the glucose standard deviation (r = −0.71), hyperglycaemia (r = −0.71) and 
hypoglycaemia (r = −0.45) [11]. At 3 month intervals over the first 2 years following 
diagnosis of type 1 diabetes we found correlation coefficients ranging from 0.36 to 0.55 for 
peak C-peptide levels and the percentage of CGM glucose values between 3.9 and 7.8 
mmol/l. We found a weaker association between the CV of glucose values and peak C-
peptide levels (r = −0.12 to −0.53) and an even weaker association between peak C-peptide 
levels and the percentage of hypoglycaemic readings (r = 0.07–0.31).
The IDAA1c has been proposed as a surrogate marker for a partial remission by Mortenson 
et al [4] who found that there was a significant correlation between the IDAA1c score and 
stimulated C-peptide levels at 12 months following diagnosis of diabetes (R2 = 0.31). Our 
results are similar to those of Mortenson et al. We found a correlation coefficient of −0.65 
between IDAA1c and stimulated peak C-peptide levels at 12 months post-diagnosis of type 1 
diabetes, with an IDAA1c level of < 9 being virtually always associated with a peak C-
peptide level > 0.2 pmol/ml. However, when IDAA1c levels were ≥ 9, C-peptide levels were 
often > 0.2 pmol/ml (ESM Fig. 4 and ESM Table 5). A similar situation was seen when 
using CGM data to predict the presence of residual C-peptide secretion. As seen in Fig. 1a, 
if > 60% of sensor values were between 3.9 and 7.8 mmol/l, 100% of patients had a peak C-
peptide > 0.2 pmol/ml; however, a large majority of patients with < 60% of their readings 
between 3.9 and 7.8 mmol/l also had positive C-peptide secretion. Glucose variability, as 
measured by the glucose CV, did not provide a clear cut point for determining C-peptide 
levels > 0.2 pmol/ml (Fig. 2).
We were initially disappointed that CGM-measured metrics did not seem to provide 
additional value to IDDA1c levels in predicting C-peptide levels. However, this is not 
completely unexpected since the CGM data reflect glucose values, similar to HbA1c, while 
the IDAA1c also adjusts for the amount of insulin the patient is taking.
Clinically, it has been commonly observed that near-normal fasting meter glucose values 
with a small standard deviation (fasting glucose values < 7.8 mmol/l and a standard 
deviation of < 2.8 mmol/l) correlate with the ‘honeymoon’ phase of diabetes. In the current 
study, if more than 50% of ‘fasting’ CGM readings (between 04:00 and 06:00 hours) were 
in the range 3.9–7.8 mmol/l there was a high probability of having a peak C-peptide level > 
0.2 pmol/ml. However, there were many individuals with 0–50% of their fasting glucose 
levels between 3.9 and 7.8 mmol/l who still had significant C-peptide levels, so overall 
fasting CGM levels did not predict peak C-peptide levels (Fig. 1b). It was even more 
surprising that there was a lack of association between C-peptide levels and CGM-measured 
hypoglycaemia. In the DCCT, maintaining residual C-peptide secretion was associated with 
a significant decrease in the incidence of severe hypoglycaemia [13]. In a previous study, a 
good correlation of residual C-peptide secretion with a lower incidence of hypoglycaemic 
readings on CGM was demonstrated [14]. In that study, 16 participants with recently 
diagnosed diabetes and measurable C-peptide levels (mean 0.96 ± 0.42 pmol/ml, ranging 
from 0.46 to 1.96 pmol/ml) had a 0.3% incidence of hypoglycaemia, and a group of 
individuals with a mean duration of diabetes of 7.6 years and who had similar HbA1c levels 
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(6.8% [51 mmol/mol]) had a 7.6% incidence of hypoglycaemia. Of interest, in that study an 
age-matched control group had 1.7% of their CGM readings < 3.9 mmol/l despite not having 
diabetes [14], which may be a result of false hypoglycaemic readings obtained with the 
CGM, which was the same CGM system as used in the current study. In the current study, 
76% of CGM downloads from study participants, more than 10% of whom had CGM 
readings < 3.9 mmol/l, showed significant residual C-peptide levels of 0.57–3.08 pmol/ml 
resulting in findings of a positive correlation between increased C-peptide levels and a 
higher incidence of hypoglycaemia. This may be explained by aggressive insulin 
management producing a higher incidence of hypoglycaemia even in individuals with 
residual C-peptide secretion.
In summary, the use of CGM holds the promise of correlating glucose levels, glucose 
variability and hypoglycaemic risk to residual C-peptide levels. With the accuracy 
limitations of the CGM sensor used in these studies (mean absolute relative difference of 
16% [15]), these correlations were no better than use of the IDAA1c. In home use, sensors 
may exhibit biofouling, which results in low sensor glucose readings; calibrations performed 
at times of rapid glucose rate of change or with inaccurate meter readings may also have 
significant impact on sensor accuracy. In addition, individual sensors may vary in accuracy 
due to the manufacturing process, and sensor artefacts can result from pressure (e.g. patients 
sleeping on sensors) [16–19]. We anticipate that newer, more accurate, quieter sensors may 
provide additional benefits in predicting C-peptide levels, but this will need to be 
determined in future studies.
Supplementary Material
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Fig. 1. 
(a) Scatter plot for peak C-peptide levels compared with the percentage of sensor glucose 
values in the range 3.9–7.8 mmol/l for each visit; (b) Scatter plot for peak C-peptide levels 
compared with the percentage of fasted sensor glucose values in the range 3.9–7.8 mmol/l at 
04:00–06:00 hours for each visit. The horizontal line shows C-peptide at 0.2 pmol/ml
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Fig. 2. 
(a) Scatter plot for peak C-peptide vs the percentage of glucose ≤3.9 mmol/l; (b) Scatter plot 
for peak C-peptide vs the CGM measured glucose CV. The horizontal line shows C-peptide 
at 0.2 pmol/ml
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Fig. 3. 
Scatter plot of 2 h stimulated C-peptide levels compared with HbA1c at each visit. The 
horizontal line shows C-peptide at 0.2 pmol/ml
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